PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
0 hedge funds and large institutions have $0 invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.
Holders
–
Holders Change
-5
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
DCM
1
DAFNA Capital Management
Los Angeles,
California
| – | – | -321,856 | Closed |
|
2
Acadian Asset Management
Boston,
Massachusetts
| – | – | -172,958 | Closed |
|
|
HLA
3
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | – | -34,208 | Closed |
|
|
IIA
4
IPG Investment Advisors
San Diego,
California
| – | – | -28,700 | Closed |
|
5
Barclays
London,
United Kingdom
| – | – | -197 | Closed |
|